tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

MXCT Stock Latest News

MaxCyte signs platform license agreement with Adicet Bio
The FlyMaxCyte signs platform license agreement with Adicet Bio
2d ago
MXCT
MaxCyte announces strategic platform licensing agreement with Anocca AB
PremiumThe Fly
MaxCyte announces strategic platform licensing agreement with Anocca AB
6d ago
MXCT
MaxCyte initiated with an Overweight at Stephens
PremiumThe Fly
MaxCyte initiated with an Overweight at Stephens
15d ago
MXCT
MaxCyte Cancels AIM Market Trading for Common Stock
PremiumCompany Announcements
MaxCyte Cancels AIM Market Trading for Common Stock
1M ago
8K
MXCT
MaxCyte Shareholders Approve Equity Plan Amendment
PremiumCompany Announcements
MaxCyte Shareholders Approve Equity Plan Amendment
2M ago
8K
MXCT
MaxCyte Announces Change in Major Holdings by BlackRock
PremiumCompany AnnouncementsMaxCyte Announces Change in Major Holdings by BlackRock
2M ago
MXCT
MaxCyte, Oribiotech team on cell therapy manufacturing
Premium
The Fly
MaxCyte, Oribiotech team on cell therapy manufacturing
2M ago
MXCT
MaxCyte and Ori Biotech Collaborate to Enhance Cell Therapy Manufacturing
Premium
Company Announcements
MaxCyte and Ori Biotech Collaborate to Enhance Cell Therapy Manufacturing
2M ago
MXCT
MaxCyte Announces Change in Voting Rights Structure
PremiumCompany Announcements
MaxCyte Announces Change in Voting Rights Structure
2M ago
MXCT
BlackRock Increases Stake in MaxCyte to 9.98%
PremiumCompany Announcements
BlackRock Increases Stake in MaxCyte to 9.98%
2M ago
MXCT
MaxCyte Expands Stock Capital Amidst Strategic Growth
PremiumCompany Announcements
MaxCyte Expands Stock Capital Amidst Strategic Growth
2M ago
MXCT
BlackRock Increases Stake in MaxCyte
PremiumCompany Announcements
BlackRock Increases Stake in MaxCyte
2M ago
MXCT
MaxCyte Announces Change in Voting Rights Structure
PremiumCompany AnnouncementsMaxCyte Announces Change in Voting Rights Structure
2M ago
MXCT
MaxCyte Announces Change in Major Shareholder Voting Rights
Premium
Company Announcements
MaxCyte Announces Change in Major Shareholder Voting Rights
2M ago
MXCT
MaxCyte Announces Change in Major Holdings by BlackRock
Premium
Company Announcements
MaxCyte Announces Change in Major Holdings by BlackRock
2M ago
MXCT
BlackRock Increases Stake in MaxCyte, Boosting Voting Rights
PremiumCompany Announcements
BlackRock Increases Stake in MaxCyte, Boosting Voting Rights
2M ago
MXCT
BlackRock Increases Stake in MaxCyte to 7.65%
PremiumCompany Announcements
BlackRock Increases Stake in MaxCyte to 7.65%
3M ago
MXCT
MaxCyte Announces Change in Major Shareholder Holdings
PremiumCompany Announcements
MaxCyte Announces Change in Major Shareholder Holdings
3M ago
MXCT
MaxCyte’s Earnings Call: Navigating Challenges and Opportunities
PremiumCompany Announcements
MaxCyte’s Earnings Call: Navigating Challenges and Opportunities
3M ago
MXCT
MaxCyte Files Form 10-Q for Q1 2025
PremiumCompany AnnouncementsMaxCyte Files Form 10-Q for Q1 2025
3M ago
MXCT
MaxCyte’s Strategic Growth and Stability: A Buy Rating by Analyst Mark Massaro
Premium
Ratings
MaxCyte’s Strategic Growth and Stability: A Buy Rating by Analyst Mark Massaro
3M ago
MXCT
MaxCyte’s Strong Financial Performance and Growth Potential Justify Buy Rating
Premium
Ratings
MaxCyte’s Strong Financial Performance and Growth Potential Justify Buy Rating
3M ago
MXCT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >